As one of the most heavily regulated industries in the European Union, the pharmaceutical sector has historically been an area of focus for the European Commission and national competition authorities, which have relentlessly used antitrust enforcement as an instrument to help achieve the wider policy objective set for the sector: supporting patients’ access to innovative and affordable medicines. In a context where EU legislation regarding pharmaceuticals is currently under review as part of the Commission’s new Pharmaceutical Strategy for Europe, the sector remains under close scrutiny of competition authorities. In this article, we analyze the most recent developments across the European Union under Article 102 TFEU. While we still wait for the ECJ’s judgment in the Servier case, which creates notable uncertainty regarding the fate of the abuse of dominance allegation, these past 18 months the focus at the EU level seems to have shifted from pay-for-delay and excessive pricing cases to patent strategies (I.) and disparagement of competing drugs as an abuse of dominant position (II.). At the national level, excessive pricing remained at the center of attention, with the Leadiant case in several EU Member States and several appeal proceedings on-going in the UK (III.).